Skip to main content

Table 4 Characteristics of patients with definite and probable stent thrombosis

From: High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention

Case Risk factors Lesions Stent number AA-MAR, % ADP-MAR, % CYP2C19 gene Use of antiplatelet drugs Time from PCI to stent thrombosis (days) Cardiac death
1 EH Multi-vessel disease 2 15.4 60.6 NA Dual-antiplatelet for 2 years 2 0
2 Smoking Left main lesion 3 42.9 60.3 NA Dual-antiplatelet for 2 years 241 1
3 EH, DM, smoking Multi-vessel disease 8 35 58.4 Poor metabolizer Dual-antiplatelet for 2 years 170 0
4 EH, smoking Multi-vessel disease 3 20 58.6 NA Dual-antiplatelet for 2 years 1 0
5 DM Multi-vessel disease 3 79.8 67.9 NA Clopidogrel for lifelong time, aspirin for half year 236 1
6 EH, smoking Pro-LAD lesion 1 50 60.5 Intermediate metabolizer Clopidogrel for 1 year, aspirin stopped by oneself at 1 month after procedure, and aspirin re-used at 1 year 455 0
7 EH Multi-vessel disease 3 20.2 63 Intermediate metabolizer Aspirin for lifelong time, clopidogrel for 1 year 12 0
8 EH, DM Multi-vessel disease 2 39 58.7 Intermediate metabolizer Dual-antiplatelet for 2 years 82 0
9 No Multi-vessel disease + left main lesion 3 49.8 61.1 NA Dual-antiplatelet for 2 years 94 1
10 EH, DM Multi-vessel disease + left main lesion 6 37 45 Poor metabolizer Dual-antiplatelet for 2 years 1 0
11 DM, smoking Multi-vessel disease 4 24.6 56.4 Poor metabolizer Dual-antiplatelet for 2 years 731 1
12 EH, DM, smoking, CKD 4 Multi-vessel disease + left main lesion 7 21.1 68 Intermediate metabolizer Dual-antiplatelet for 2 years 617 1
13 Smoking Multi-vessel disease 2 34.6 57.2 Intermediate metabolizer Dual-antiplatelet for 2 years 42 1
14 EH Multi-vessel disease 6 45.4 60.3 Intermediate metabolizer Dual-antiplatelet for 2 years 138 1
  1. EH essential hypertension, DM diabetes mellitus, CKD chronic kidney disease, LAD left anterior descending, AA arachidonic acid, MAR maximal aggregation ratio, ADP adenosine diphosphate, PCI percutaneous coronary intervention
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us